PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 16, 2023Journal of Clinical Medicine2 citationsOpen Access

Favorable Prognosis in Patients with Recovered Pulmonary Hypertension after TAVI: An Analysis of the LAPLACE-TAVI Registry

View Full Paper
TKTakuma KoikeHIHiroshi IwataYCYuichi Chikata

Key Result

A 10 mmHg decrease in transtricuspid pressure gradient after TAVI was associated with a reduced risk of cardiovascular death and heart failure hospitalization (HR 0.76; 95% CI 0.64-0.90; p=0.0020).

Study Design

Type

Observational (n=2,056)

Multicenter

Yes

Structured PICO

Does the recovery of pulmonary hypertension after TAVI reduce the composite of cardiovascular death and heart failure hospitalization in patients with aortic stenosis?

P
Population
2,056 patients with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) from a prospective multi-center registry involving six Japanese centers.
I
Intervention
Recovery of pulmonary hypertension (TRPG < 30 mmHg) after TAVI
C
Comparator
Persistent pulmonary hypertension (TRPG ≥ 30 mmHg) after TAVI
O
Outcome
Composite of cardiovascular (CV) death and heart failure hospitalizationcomposite

Recovery of pulmonary hypertension after TAVI is associated with a significantly reduced risk of cardiovascular death and heart failure hospitalization.

Main Result

Effect estimate: HR 0.76 (95% CI 0.64-0.90)

p-value: p=0.0020

Abstract

Pulmonary hypertension (PH) is a common complication of aortic stenosis (AS). Despite the established association between PH and poor outcomes in patients with AS, the prognostic implication of a change in PH after transcatheter aortic valve implantation (TAVI) has been rarely evaluated. This study analyzed a prospective multi-center TAVI registry database involving six Japanese centers and used the transtricuspid pressure gradient (TRPG) obtained by echocardiography to estimate pulmonary artery systolic pressure. The participants (n = 2056) were first divided into two groups by TRPG before TAVI, a PH (−) group (TRPG < 30 mmHg) (n = 1407, 61.9%) and a PH (+) group (TRPG ≥ 30 mmHg) (n = 649, 28.6%). Next, by TRPG after (4.1 ± 5.3 days) TAVI, the PH (+) group was further subdivided into two groups, Recovered PH (TRPG < 30 mmHg, n = 253) and Persistent PH (TRPG after TAVI ≥ 30 mmHg, n = 396). The median follow-up duration was 1.8 years. The primary and secondary endpoints were the composite and each of cardiovascular (CV) death and heart failure hospitalization, respectively. Unadjusted Kaplan-Meier estimates with log-rank comparisons showed significantly higher cumulative incidences of primary and secondary endpoints in the Persistent PH group compared to other groups. Moreover, adjusted multivariate Cox-proportional hazard analyses showed that a decreased (−10 mmHg) TRPG after TAVI was linearly associated with a reduced risk of the primary endpoint (hazard ratio (HR): 0.76, 95% confidence interval (CI): 0.64−0.90, p = 0.0020). The findings in the present study indicate that the recovery of PH may partly contributes to the prognostic benefit of TAVI procedure in patients with AS and elevated pulmonary artery systolic pressure.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Koike et al. (2023) conducted an observational in Aortic stenosis with pulmonary hypertension (n=2,056). Decreased TRPG (-10 mmHg) after TAVI vs. Persistent pulmonary hypertension was evaluated on Composite of cardiovascular death and heart failure hospitalization (HR 0.76, 95% CI 0.64-0.90, p=0.0020). A 10 mmHg decrease in transtricuspid pressure gradient after TAVI was associated with a reduced risk of cardiovascular death and heart failure hospitalization (HR 0.76; 95% CI 0.64-0.90; p=0.0020).

synapsesocial.com/papers/6a0eb6ea8da6dd046147a86dhttps://doi.org/10.3390/jcm12020729
Ask AI
Helpful
Bookmark
Share
View Full Paper